Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | MELK | Q14680 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12657532 | 0.90 | KMT2A (0.49) | CDC7MAP4K4CDK8DYRK1AMELK | |
| SCHEMBL12657781 | 0.87 | GRM5 (0.56) | SMN1; SMN2GRM5KMT2AMEN1 | |
| SCHEMBL12657584 | 0.85 | CNR2 (0.47) | MAPK1CDC7MAP4K4CDK8DYRK1A | |
| SCHEMBL8942516 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2CDC7MAP4K4CDK8DYRK1A | |
| SCHEMBL12657594 | 0.79 | BTK (0.42) | MAPK1GRM5 | |
| SCHEMBL12657778 | 0.77 | HPGD (0.43) | SMN1; SMN2 | |
| SCHEMBL12707491 | 0.77 | ROCK1 (0.43) | SMN1; SMN2HSD17B10KMT2AMEN1 | |
| SCHEMBL12707496 | 0.76 | MAPK1 (0.40) | MAPK1 | |
| SCHEMBL935499 | 0.75 | CDC7 (0.66) | MAPK1SMN1; SMN2CDC7MAP4K4CDK8 | |
| SCHEMBL13180661 | 0.73 | GRM5 (0.53) | MAPK1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096302-A1 | PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2013-04-18 | — | — | US | disclosed |
| US-20130096302-A1 | PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2013-04-18 | — | — | US | disclosed |
| US-8372835-B2 | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372835-B2 | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110081364-A1 | PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2011-04-07 | — | — | US | disclosed |
| US-20110081364-A1 | PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2011-04-07 | — | — | US | disclosed |
| US-7795259-B2 | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795259-B2 | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096302-A1 | PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | AURKC, AURKA, PLK1 | MAPK1 390/4885SMN1; SMN2 2771/4885CDC7 71/4885 |
| US-20110081364-A1 | PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES | AURKC, AURKA, PLK1 | MAPK1 390/4885SMN1; SMN2 2771/4885CDC7 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.